Effect of Omalizumab in the Skin of Food Allergy Patients

PHASE4RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

September 30, 2026

Study Completion Date

December 31, 2026

Conditions

Food AllergyFood Allergy in Children

Interventions

DRUG

Omalizumab Injection

Omalizumab is a monoclonal antibody FDA-approved for treatment of food allergy.

Trial Locations (1)

RECRUITING

National Jewish Health, Denver

All Listed Sponsors

collaborator

Roche-Genentech

INDUSTRY

lead

National Jewish Health

OTHER